Dignitana signs OncoMedical for distribution in Switzerland and Liechtenstein
Comunicato Precedente
Comunicato Successivo
"Scalp cooling with DigniCap Delta is a significant advancement in quality of life for cancer patients, said Simon Dätwyler, CEO of OncoMedical. "Customers want the most advanced treatments to ensure optimal patient outcomes. We are happy to add DigniCap to our suite of top tier medical technologies and are eager to expand availability of DigniCap in this region."
"OncoMedical shares our commitment to excellence in technology, customer service and patient care," said Catarina Löwenadler, CEO of Dignitana. "As we continue to expand patient access, Dignitana is strengthened by utilizing local market experts like OncoMedical to ensure customers receive the best possible service and attention."
The FDA-cleared DigniCap Scalp Cooling System minimizes hair loss from chemotherapy for cancer patients with solid tumors such as breast, prostate and gynecological cancers. With over 7,400 new breast cancer cases and 6,500 new prostate cancer cases diagnosed each year, these are the two most prevalent types of cancer in Switzerland.
Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is listed as a treatment recommendation in the clinical practice guidelines published by European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network® (NCCN) in the US, and Cancer Australia.
For More Information Contact
Melissa Bourestom, Chief Communications Officer, melissa.bourestom@dignitana.com +1 469-518-5031
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/dignitana-signs-oncomedical-for-distribution-in-switzerland-and-liechtenstein-302034653.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
